Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...

Roche is narrowing its pipeline to 11 disease areas and continuing to invest in a targeted way, said Teresa Graham, chief ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

The technological innovation is an expansion of the NOBIVAC NXT platform, and a breakthrough achievement against one of the ...

Ethereum, or 1 ETH, traded at $2,636.77 as of 8 a.m. ET. The highest intraday price the cryptocurrency reached in the past ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

Merck Foundation  FASHION Awards “More Than a Mother” to address one or more of the following social issues such as: Breaking Infertility Stigma, Supporting Girl, Ending Child Marriage, Ending FGM, St ...

AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...

Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company’s diverse pipeline of proprietary intracellular ...

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 ...

In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients. The agreement sees San Diego-based Janux in ...